Apoptosis
Aminopeptidase
Products > Metabolic Enzyme/Protease > Acetyl-CoA Carboxylase > ND-630 (Synonyms: GS-0976; NDI-010976; firsocostat)
|
Product name : ND-630 (Synonyms: GS-0976; NDI-010976; firsocostat)
Item : c2365
Price : 200mg, $1750;500mg, $2890; 1g, $3950;
contact : Send inquiry to: info@acesobio.com
CAS : 1434635-54-7
Molecular Weight : 569.629
Formula : C28H31N3O8S
Storage : at -20°C
Additional information : We offer significant discount for bulky quantity order.
 |
| Details: |
Description of:ND-630 (Synonyms: GS-0976; NDI-010976; firsocostat)
ND-630(CAS:1434635-54-7)is an acetyl-CoA carboxylase (ACC) inhibitor; inhibits human ACC1 and ACC2 with IC50 values of 2.1 and 6.1 nM, respectively. ND-630 nteracts within the ACC phosphopeptide acceptor and dimerization site to prevent dimerization and inhibit the enzymatic activity of both ACC isozymes, reduce fatty acid synthesis and stimulate fatty acid oxidation in cultured cells and in animals, and exhibit favorable drug-like properties. ND-630 reduces hepatic steatosis, improves insulin sensitivity, reduces weight gain without affecting food intake, and favorably affects dyslipidemia. When administered chronically to Zucker diabetic fatty rats, ND-630 reduces hepatic steatosis, improves glucose-stimulated insulin secretion, and reduces hemoglobin A1c (0.9% reduction) Quality control data: Quality control by 1H-NMR, 13C-NMR, HPLC and LCMS. Product will be shipped with supporting analytical data. REFERENCES1: Harriman G, Greenwood J, Bhat S, Huang X, Wang R, Paul D, Tong L, Saha AK,Westlin WF, Kapeller R, Harwood HJ Jr. Acetyl-CoA carboxylase inhibition by ND-630 reduces hepatic steatosis, improves insulin sensitivity, and modulates dyslipidemia in rats. Proc Natl Acad Sci U S A. 2016 Mar 29;113(13):E1796-805. doi: 10.1073/pnas.1520686113. PubMed PMID: 26976583; PubMed Central PMCID: PMC4822632. |
| Related Products : |
|
|
Chinese
Deutsch
Espanol
Francais
Italiano
Portugues
Japanese
Korean
Arabic
Russian